

primary adenocarcinomas of the prostate is significant in that efforts to establish long-term cultures of cells of this type have been exceptionally difficult.

The present invention describes the characterization of single cell clones derived from the prostate tumor cell lines disclosed in the earlier application. These new clones exhibit traits which may indicate their usefulness as an in vitro model of human prostate cancer. The single cell clones are paired normal and tumor cell clones where the latter exhibit allelic loss of heterozygosity (LOH) indicating the presence of unique genetic deletions. This loss may suggest that these cells express unique proteins or antigens which might be of tremendous value in prostate cancer research. The subject matter of both the parent and CIP applications were combined in a subsequent PCT application filed January 30, 1997.

Possible uses of these cells include testing various anti-cancer agents and subtraction studies for identification of gene deletions. These lines could establish a new basis for possible cancer vaccines and also be used to develop monoclonal antibodies against specific prostate cancer antigens. (portfolios: Cancer—Therapeutics, vaccines; Cancer—Therapeutics, immunomodulators and immunostimulants)

Macrophage Migration Inhibitory Factor (MIF)

Graeme J. Wistow (NEI)
Serial No. 08/202,486 filed 28 Feb 94
(allowed); DIV of U.S. Patent
5,328,990 issued 12 Jul 94
Licensing Contact: Jaconda Wagner,
301/496-7735 ext 284

The protein known as macrophage migration inhibitory factor (MIF) was one of the first cytokines to be discovered. Thirty-years ago it was described as a T-cell-derived factor that inhibited the random migration of macrophages in vitro. Today, MIF is known to be a mediator of the function of macrophages in host defense and its expression correlates with delayed hypersensitivity and cellular immunity. It plays an important role in the inflammatory response and is associated with cell differentiation. As with other lymphokines, MIF could have therapeutic values in stimulating the immune system and other cells. Hardly abundant from other sources, the high concentration of the protein that has been found in the eye lens could be a useful source for research. The present invention provides the DNA that encodes MIF. A related invention

provides a method for isolating MIF from the ocular lens. (portfolio: Ophthalmology—Therapeutics; Internal Medicine—Therapeutics, anti-inflammatory)

Dated: April 28, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-12783 Filed 5-14-97; 8:45 am]

BILLING CODE 4140-01-W

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the President's Cancer Panel. This meeting will be closed in accordance with the provisions of section 552b(c)(9)(B), Title 5, U.S.C., for discussion and preparation of the Annual Report of the Chair to the President for 1996. These discussions could disclose information, the premature disclosure of which would be likely to significantly frustrate implementation of proposed action the Panel may plan to take.

Linda Quick-Cameron, Committee Management Officer, National Cancer Institute, Executive Plaza North, Room 630E, 6130 Executive Blvd., MSC 7410, Bethesda, MD 20892-7410 (301/496-5708) will provide a summary of the meeting and the roster of committee members upon request. Other information pertaining to the meeting may be obtained from the contact person indicated below.

Committee Name: President's Cancer Panel.

Date: May 22, 1997.

Place: La Guardia Marriott, 102-05 Ditmars Boulevard, E. Elmhurst, New York 11369.

Closed: 8:30 a.m. to 5:30 p.m.

Agenda: Finalization of the Annual Report of the Chairman to the President.

Contact Person: Maureen O. Wilson, Ph.D., Executive Secretary, National Cancer Institute, Building 31, Room 4A48, Bethesda, MD 20892-2473, Telephone: (301) 496-1148.

This notice is being published less than 15 days prior to the meeting due to the urgent need to proceed with the finalization of the Annual Report of the Chairman to the President.

Dated: May 8, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-12781 Filed 5-14-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Meeting; National Arthritis and Musculoskeletal and Skin Diseases Advisory Council

Pursuant to Pub. L. 92-463, notice is hereby given of a meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council to provide advice to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) on June 5, 1997, in Conference Room 6, Building 31, National Institutes of Health, Bethesda, Maryland.

The meeting will be open to the public June 5 from 8:30 a.m. to 12:00 p.m. to discuss administrative details relating to Council business and special reports. Attendance by the public will be limited to space available.

The meeting of the Advisory Council will be closed to the public on June 5 from 1:00 p.m. to adjournment in accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. and sec. 10(d) of Pub. L. 92-463, for the review, discussion and evaluation of individual grant applications. These deliberations could reveal confidential trade secrets or commercial property, such as patentable material, and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal property.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Dr. Steven Hausman, Executive Secretary, National Arthritis and Musculoskeletal and Skin Diseases Advisory Council, NIAMS, Natcher Building, Room 5AS-13, Bethesda, Maryland 20892 (301) 594-2463.

A summary of the meeting and roster of the members may be obtained from the Extramural Programs Office, NIAMS, Natcher Building, Room 5AS-13, National Institutes of Health, Bethesda, Maryland 20892 (301) 594-2463.

(Catalog of Federal Domestic Assistance Program No. 93.846, Arthritis, Bone and Skin Diseases, National Institutes of Health)

Dated: May 9, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-12778 Filed 5-14-97; 8:45 am]

BILLING CODE 4140-01-M